Results 1 to 10 of about 697 (106)

Des-gamma-carboxyprothrombin is a favorable biomarker for the early diagnosis of alfa-fetoprotein-negative hepatitis B virus-related hepatocellular carcinoma [PDF]

Journal of International Medical Research, 2020
Objectives Des-gamma-carboxyprothrombin (DCP) is an important serum biomarker for the clinical screening of hepatocellular carcinoma (HCC). This study aimed to evaluate the value of DCP for the early diagnosis of alpha-fetoprotein (AFP)-negative ...
Zhaobo Liu, Min Wu, Dongdong Lin, Ning Li   +3 more
doaj   +3 more sources

Prognostic Values of Alpha-Fetoprotein and Des-Gamma-Carboxyprothrombin in Hepatocellular Carcinoma in China: An Analysis of 4792 Patients [PDF]

Journal of Hepatocellular Carcinoma, 2021
Yang-Xun Pan,1– 3,* Xu-Qi Sun,1,2,* Zi-Li Hu,1,2,* Wa Xie,1,2 Ke-Xin Nie,4 Ai-Ping Fang,5 Ying-Yao Zhang,4 Yi-Zhen Fu,1,2 Jin-Bin Chen,1,2 Jun-Cheng Wang,1,2 Xin Wang,1,2 Yao-Jun Zhang,1,2 Dan-Dan Hu,1,2 Min-Shan Chen1,2 1Collaborative ...
Pan YX, Sun XQ, Hu ZL, Xie W, Nie KX, Fang AP, Zhang YY, Fu YZ, Chen JB, Wang JC, Wang X, Zhang YJ, Hu DD, Chen MS   +13 more
doaj   +2 more sources

Diagnostic value of alpha-fetoprotein, agglutinin-reactive alpha-fetoprotein, and des-gamma-carboxyprothrombin in hepatitis B virus-related hepatocellular carcinoma [PDF]

Journal of International Medical Research, 2020
Objective This study aimed to explore the use of different combinations of alpha-fetoprotein (AFP), Lens culinaris agglutinin-reactive AFP (AFP-L3), and des-gamma-carboxyprothrombin (DCP) for the early diagnosis of hepatocellular carcinoma (HCC) in ...
Ting Song, Lili Wang, Bin Su, Weiping Zeng, Taiyi Jiang, Tong Zhang, Guizhen Sun, Hao Wu   +7 more
doaj   +2 more sources

Comparison of Interferon-Based and Interferon-Free Treatments on the Prognosis of Hepatocellular Carcinoma After Hepatitis C Virus-Sustained Virological Response: A Multicenter Study. [PDF]

Cancer Med
ABSTRACT Aim We examine the impact of interferon (IFN)‐based and IFN‐free treatment on the prognosis of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) sustained virological response (SVR). Methods Clinical information was collected on 311 cases of HCC after HCV‐SVR from 16 facilities affiliated with the Kyushu Liver Surgery Study Group ...
Itoh S, Iseda N, Yoshizumi T, Ide T, Noshiro H, Sakai H, Hisaka T, Nakashima M, Nagano H, Okabe H, Hayashi H, Miyoshi A, Kitahara K, Takami Y, Nanashima A, Kuroki T, Endo Y, Okamoto K, Kajiwara M, Sakoda M, Beppu T, Takatsuki M, Eguchi S.   +22 more
europepmc   +2 more sources

Early Tumor Marker Response Predicts Treatment Outcomes in Patients with Unresectable Hepatocellular Carcinoma Receiving Combined Lenvatinib, Immune Checkpoint Inhibitors, and Transcatheter Arterial Chemoembolization Therapy [PDF]

Journal of Hepatocellular Carcinoma, 2023
Meng-Chao Luo,1,2,* Jia-Yi Wu,1,3,* Jun-Yi Wu,1,3 Zhong-Tai Lin,1,2 Yi-Nan Li,3 Zhen-Xin Zeng,3 Shao-Ming Wei,1,2 Mao-Lin Yan1,3 1Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian Province, 350001, People’s Republic of
Luo MC, Wu JY, Wu JY, Lin ZT, Li YN, Zeng ZX, Wei SM, Yan ML   +7 more
doaj   +2 more sources

Effect of abdominal aortic calcification on long‐term outcomes after the first liver resection in very old patients with hepatocellular carcinoma [PDF]

Annals of Gastroenterological Surgery
Aim We previously reported that abdominal aortic calcification is associated with poor overall and recurrence‐free survival after hepatectomy for hepatocellular carcinoma (HCC).
Yosuke Namba, Masahiro Ohira, Yuki Imaoka, Michinori Hamaoka, Masakazu Hashimoto, Takashi Onoe, Daisuke Takei, Koichi Oishi, Megumi Yamaguchi, Tomoyuki Abe, Takeshi Tadokoro, Sotaro Fukuhara, Ko Oshita, Keiso Matsubara, Naruhiko Honmyo, Shintaro Kuroda, Hiroyuki Tahara, Tsuyoshi Kobayashi, Kentaro Ide, Hideki Ohdan   +19 more
doaj   +2 more sources

Diagnostic Value of MR Elastography and MRI-Proton Density Fat Fraction in Cirrhosis Based on Explant Liver Histology. [PDF]

J Gastroenterol Hepatol
ABSTRACT Background and Aims Accurate assessment of advanced fibrosis and steatosis is essential for prognostication in chronic liver disease. This study aimed to evaluate the diagnostic performance of MRI in assessing liver fibrosis and steatosis in patients undergoing liver transplantation (LT).
Min EK, Kim SS, Ahn B, Kim DG, Joo DJ, Ahn SH, Kim SU, Lee JG.   +7 more
europepmc   +2 more sources

Economic evaluation of biomarker-based surveillance for Hepatocellular Carcinoma in Thai patients with Compensated Liver Cirrhosis. [PDF]

PLoS ONE
ObjectiveHepatocellular carcinoma (HCC) is the leading cause of cancer-related death in Thailand. However, most Thai patients at high risk of HCC lack access to routine surveillance programs.
Nutcha Pinjaroen, Wirichada Pan-Ngum, Kittiyod Poovorawan, David Wastlund, Fabian Mueller, Peng Lu, Rebecca Sim Shu Yu, Pisit Tangkijvanich   +7 more
doaj   +2 more sources

Challenges in the Diagnosis of Hepatocellular Carcinoma in a 32-Year-Old Male With Hepatitis B and Alcohol Use. [PDF]

Clin Case Rep
ABSTRACT Hepatitis B induced hepatocellular carcinoma (HCC) is an important cause of morbidity and mortality in sub‐Saharan Africa and particularly in Zambia presenting at a younger age compared to other regions globally and with poorer prognosis.
Syabbalo E, Mwanza N, Kaoma D, Shumbwa C, Chibuta P, Mulopwe J, Mupeta S, Mubbunu M, Sinkala E.   +8 more
europepmc   +2 more sources

Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child-Pugh Class B. [PDF]

Liver Int
ABSTRACT Background & Aims Despite the advances in systemic therapy for unresectable hepatocellular carcinoma (HCC), patients with Child–Pugh class B (CP‐B) liver function face a significant unmet need. This study evaluated the efficacy and safety of atezolizumab plus bevacizumab (Atez/Bev) in patients with unresectable HCC and CP‐B.
Sasaki R, Shimose S, Saeki I, Ito T, Takeuchi Y, Tani J, Tomonari T, Sasaki K, Kakizaki S, Hatanaka T, Miuma S, Shirono T, Iwamoto H, Tanabe N, Yamamoto T, Kanayama Y, Naganuma A, Nishina S, Takayama T, Kobara H, Otsuka M, Kawashima H, Takami T, Kawaguchi T, Miyaaki H, Hepatology InVestigator Experts in Japan (HIVE‐J) Study Group.   +25 more
europepmc   +2 more sources